Literature DB >> 22550377

Anticoagulation management.

Blaze W Cook1.   

Abstract

To perform safe invasive procedures on patients on anticoagulation therapy, management of the patient's anticoagulation status is mandatory. For patients on anticoagulation therapy, a risk analysis of both the procedural risk of bleeding as well as the risk to the patient from discontinuing anticoagulation needs to be performed. For procedures at low risk of bleeding, the procedure may be performed with little change to the patient's anticoagulation regimen. For procedures with significant bleeding risk, however, anticoagulation will need to be held or reversed. Patients at high risk for thromboembolic complications will require bridging therapy if anticoagulation is to be withheld. In this article, a logical assessment of bleeding risk in patients undergoing procedures is presented, and a review of anticoagulation and risk is discussed.

Entities:  

Keywords:  Anticoagulation; bleeding; heparin; warfarin

Year:  2010        PMID: 22550377      PMCID: PMC3324206          DOI: 10.1055/s-0030-1267849

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  18 in total

1.  Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

Authors:  R Kubalek; A Berlis; M Schwab; J Klisch; M Schumacher
Journal:  Neuroradiology       Date:  2003-03-28       Impact factor: 2.804

2.  ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.

Authors:  Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel
Journal:  J Am Coll Cardiol       Date:  2006-08-01       Impact factor: 24.094

3.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

4.  A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.

Authors:  Benny Sørensen; Jørgen Ingerslev
Journal:  Thromb Haemost       Date:  2006-10       Impact factor: 5.249

Review 5.  The effects of heparin and low molecular weight heparins on bone.

Authors:  Raghav Rajgopal; Mackenzie Bear; Martin K Butcher; Stephen G Shaughnessy
Journal:  Thromb Res       Date:  2007-08-22       Impact factor: 3.944

6.  The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.

Authors:  R A Raschke; B M Reilly; J R Guidry; J R Fontana; S Srinivas
Journal:  Ann Intern Med       Date:  1993-11-01       Impact factor: 25.391

7.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  James D Douketis; Peter B Berger; Andrew S Dunn; Amir K Jaffer; Alex C Spyropoulos; Richard C Becker; Jack Ansell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution.

Authors:  L J Collins; D I Silverman; P S Douglas; W J Manning
Journal:  Circulation       Date:  1995-07-15       Impact factor: 29.690

Review 10.  Outpatient management of anticoagulation therapy.

Authors:  Anne L du Breuil; Elena M Umland
Journal:  Am Fam Physician       Date:  2007-04-01       Impact factor: 3.292

View more
  7 in total

1.  Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.

Authors:  Nousjka P A Vranken; Amber J A J Theelen; Tamar Orbons; Paul J C Barenbrug; Patrick W Weerwind
Journal:  J Extra Corpor Technol       Date:  2021-03

2.  Therapeutic Dilemmas Regarding Anticoagulation: An Experience in a Patient with Nephrotic Syndrome, Pulmonary Embolism, and Traumatic Brain Injury.

Authors:  Tetsu Akimoto; Tomoyuki Yamazaki; Eiji Kusano; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2016-11-03

3.  Retroperitoneal Bleeding: An Experience During Prophylactic Anticoagulation in a Patient With Nephrotic Syndrome.

Authors:  Mari Okada; Tetsu Akimoto; Mutsumi Kawamata; Toshimi Imai; Erika Hishida; Marina Kohara; Atsushi Miki; Takuya Murakami; Taro Sugase; Takahiro Masuda; Yuko Ono; Yoshihiko Ueda; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2017-08-01

4.  Is Intravenous Heparin a Contraindication for TPA in Ischemic Stroke?

Authors:  Zain Kulairi; Nisha Deol; Renee Tolly; Rohan Manocha; Maliha Naseer
Journal:  Case Rep Neurol Med       Date:  2017-02-05

Review 5.  Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants.

Authors:  Osamu Kumano; Kohei Akatsuchi; Jean Amiral
Journal:  Biomedicines       Date:  2021-03-07

6.  Fatal Ovarian Hemorrhage Associated With Anticoagulation Therapy in a Yucatan Mini-Pig Following Venous Stent Implantation.

Authors:  Sophie Boorman; Hope Douglas; Bernd Driessen; Matthew J Gillespie; Thomas P Schaer
Journal:  Front Vet Sci       Date:  2020-01-30

7.  Redox-Responsive Heparin-Chlorambucil Conjugate Polymeric Prodrug for Improved Anti-Tumor Activity.

Authors:  Abegaz Tizazu Andrgie; Yihenew Simegniew Birhan; Tefera Worku Mekonnen; Endiries Yibru Hanurry; Haile Fentahun Darge; Rong-Ho Lee; Hsiao-Ying Chou; Hsieh-Chih Tsai
Journal:  Polymers (Basel)       Date:  2019-12-27       Impact factor: 4.329

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.